La chaîne d'options affiche les données clés des options sur actions de SILO Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour SILO Pharma..

SILO Pharma (NASDAQ:SILO) Stock, Chaîne d'Options

SILO Pharma

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

SILO Pharma Inc

Silo Wellness Inc

Press Releases

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Silo Pharma Enters into Letter of Intent for JV with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

News

Legal

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

HOTH

SILO

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aditxt

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Ensysce Biosciences

Entero Therapeutics

Galecto

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Oragenics

Onconetix

Palisade Bio

Polyrizon

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Sunshine Biopharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

Xenetic Biosciences

Laidlaw & Co.

Screenshot 2024-05-21 at 6.46.56 PM

Biotech

General

ATAI

FTRP

Revolutionizing Mental Healthcare With The Rise Of Ketamine And Psychedelic Therapies

Comments

SILO Pharma

SILO Pharma (SILO) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL